BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11112213)

  • 1. Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens.
    Perez RP; Zhang P; Bosserhoff AK; Buettner R; Abu-Hadid M
    Hum Pathol; 2000 Nov; 31(11):1381-8. PubMed ID: 11112213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative assessment of the expression of melanoma-associated antigens by non-competitive reverse transcription polymerase chain reaction.
    Ringhoffer M; Schmitt M; Karbach J; Jäger E; Oesch F; Arand M
    Int J Oncol; 2001 Nov; 19(5):983-9. PubMed ID: 11604998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
    Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
    Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
    de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
    Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood.
    de Vries TJ; Fourkour A; Punt CJ; Diepstra H; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(6):1066-70. PubMed ID: 10576666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method.
    Arenberger P; Arenbergerova M; Gkalpakiotis S; Lippert J; Stribrna J; Kremen J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):56-64. PubMed ID: 18181974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma-associated antigens as messenger RNA detection markers for melanoma.
    Sarantou T; Chi DD; Garrison DA; Conrad AJ; Schmid P; Morton DL; Hoon DS
    Cancer Res; 1997 Apr; 57(7):1371-6. PubMed ID: 9102226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
    Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
    J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients.
    Enk CD; Lotem M; Gimon Z; Hochberg M
    Melanoma Res; 2004 Oct; 14(5):361-5. PubMed ID: 15457091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.
    Scoggins CR; Ross MI; Reintgen DS; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Davidson BS; Sussman JJ; Edwards MJ; Martin RC; Lewis AM; Stromberg AJ; Conrad AJ; Hagendoorn L; Albrecht J; McMasters KM
    J Clin Oncol; 2006 Jun; 24(18):2849-57. PubMed ID: 16782924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
    de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
    J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RT-PCR detection of tyrosinase, gp100, MART1/Melan-A, and TRP-2 gene transcripts in peripheral blood of melanoma patients.
    Samija M; Juretić A; Solarić M; Samija I; Bingulac-Popović J; Grahovac B; Stanec M; Oresić V
    Croat Med J; 2001 Aug; 42(4):478-83. PubMed ID: 11471202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional reverse transcription-polymerase chain reaction of peripheral slices is not superior to analysis of the central slice in sentinel lymph nodes from melanoma patients.
    Blaheta HJ; Roeger S; Sotlar K; Schittek B; Breuninger H; Bueltmann B; Garbe C
    Br J Dermatol; 2004 Mar; 150(3):477-83. PubMed ID: 15030330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients.
    Rapanotti MC; Bianchi L; Ricozzi I; Campione E; Pierantozzi A; Orlandi A; Chimenti S; Federici G; Bernardini S
    Br J Dermatol; 2009 Feb; 160(2):338-44. PubMed ID: 19067715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the role of sequential reverse-transcriptase polymerase chain reaction analysis of melanoma-specific mRNA in the peripheral blood of melanoma patients?
    Quaglino P; Osella-Abate S; Savoia P; Bernengo MG; Cappello N; Cavallo F
    J Clin Oncol; 2007 Mar; 25(9):1140-1; author reply 1141-2. PubMed ID: 17369579
    [No Abstract]   [Full Text] [Related]  

  • 17. Detection of tyrosinase mRNA from the blood of melanoma patients.
    Stevens GL; Scheer WD; Levine EA
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):293-6. PubMed ID: 8722221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance.
    Gradilone A; Ribuffo D; Silvestri I; Cigna E; Gazzaniga P; Nofroni I; Zamolo G; Frati L; Scuderi N; Aglianò AM
    Ann Surg Oncol; 2004 Nov; 11(11):983-7. PubMed ID: 15525827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p54nrb is a new regulator of progression of malignant melanoma.
    Schiffner S; Zimara N; Schmid R; Bosserhoff AK
    Carcinogenesis; 2011 Aug; 32(8):1176-82. PubMed ID: 21642354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
    de Vries TJ; Fourkour A; Punt CJ; van de Locht LT; Wobbes T; van den Bosch S; de Rooij MJ; Mensink EJ; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 May; 80(5-6):883-91. PubMed ID: 10360670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.